Article: Targeted Genetics Corporation and Medeva PLC Form Collaboration to Develop Gene Therapy Product to Treat Cystic Fibrosis.

Agreement Covers Development and Commercialization of tgAAV-CF

SEATTLE, Nov. 24 /PRNewswire/ -- Targeted Genetics Corporation (Nasdaq: TGEN) and Medeva PLC (NYSE: MDV) today announced the formation of a collaboration to develop and commercialize tgAAV-CF, Targeted Genetics' potential gene therapy product for the treatment of cystic fibrosis (CF). The tgAAV-CF product candidate uses Targeted Genetics' proprietary adeno-associated virus (AAV) technology to deliver a normal copy of the CFTR gene to patients with CF.

Under the terms of the agreement, Targeted Genetics could receive up to $54 million, including $12 million of loans. The consideration being ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!